{"prompt": "['MC1575', '69', 'Amendment 2', 'Appendix III Potential drugs that could interact with lenvatinib (via CYP 3A4)', 'Inhibitors and inducers of CYP3A are shown below. A comprehensive list of inhibitors can be found at', 'the following website: :http://medicine.iupui.edu/clinpharm/ddis/table.aspx. . The general categorization', 'into strong, moderate, and weak inhibitors according to the website is displayed below.', 'Inhibitors of CYP3A', 'Inducers of CYP3A', 'Strong inhibitors:', 'Carbamazepine', 'INDINAVIR', 'Efavirenz', 'NELFINAVIR', 'Nevirapine', 'RITONAVIR', 'Barbiturates', 'CLARITHROMYCIN', 'Glucocorticoids', 'ITRACONAZOLE', 'Modafinil', 'KETOCONAZOLE', 'Oxcarbarzepine', 'NEFAZODONE', 'Phenobarbital', 'Posaconazole', 'Phenytoin', 'SAQUINAVIR', 'Pioglitazone', 'SUBOXONE', 'Rifabutin', 'TELITHROMYCIN', 'Rifampin', 'Voriconazole', \"St. John's Wort\", 'Moderate inhibitors:', 'Troglitazone', 'Aprepitant', 'Erythromycin', 'Diltiazem', 'Fluconazole', 'grapefruit juice', 'Seville orange juice', 'Verapamil', 'Weak inhibitors:', 'Cimetidine', 'All other inhibitors:', 'Amiodarone', 'NOT azithromycin', 'Chloramphenicol', 'Boceprevir', 'Ciprofloxacin', 'Delaviridine', 'diethyl-dithiocarbamate', 'Fluvoxamine', 'Gestodene', 'Imatinib', 'Mibefradil', 'Mifepristone', 'Norfloxacin', 'Norfluoxetine', 'star fruit', 'Telaprevir', 'Troleandomycin', 'Protocol Version Date: :16Aug2018']['MC1575', '70', 'Amendment 2', 'Appendix IV Hypertension Management Guidelines', 'D.1. Guidelines for the management of lenvatinib-Induced Hypertension:', 'Non-secretory tumors', '(For secretory tumors please see Section D.2.)', 'Increases in blood pressure (BP) and cases of hypertension have been associated with many', 'drugs acting on the VEGF pathway. The proposed mechanism for this increase is through', 'inhibition of VEGF-induced peripheral vasodilation. Hypertension following lenvatinib is', 'well documented in clinical trials. With secretory paraganglioma and pheochromocytoma this', 'could be a major toxicity.', 'NOTE: that hypertension management of secretory tumors is more complex due to the', 'additional risk of hypertension issues in these patients and management is discussed', 'separately below. For example consultation with HTN specialist is required in patients with', 'secretory tumors prior to study initiation.', 'While subjects are receiving treatment with lenvatinib, the early initiation of', 'antihypertensive treatment for grade 1 or 2 hypertension to minimize more severe or', 'persistent hypertension is not considered a grade 3 AE.', 'Decisions to hold or decrease the lenvatinib dose during treatment must be based on BP', 'readings taken in the clinic by a medical professional.', 'Recommended Hypertension Monitoring and Management for non-', 'secretory tumors (BP in mmHg)', 'Grade', 'Antihypertensive', 'Blood Pressure', 'Lenvatinib', '(CTCAE v4)', 'Therapy', 'Monitoring', 'Dose Modification', 'Persistent* Grade 1', 'Standard', 'No Change', 'Pre-hypertension', 'Systolic 120-139', 'Diastolic 80-90', 'Persistent Grade 2-', 'Step 1) Initiate anti-', 'BP should be', 'No change except as', 'Moderate', 'hypertensive treatment', 'monitored as', 'described in Step 4', 'Systolic 140-159', '(calcium channel', 'recommended by the', 'Diastolic 90-99', 'blocking agents, e.g.', 'treating physician', 'amlodipine, are generally', 'Protocol-specific', 'the preferred agents) and', 'guidance supersedes', 'if needed, after 24-48 hr', 'any other management', 'Rx, increase dose in', 'guidelines, including', 'stepwise fashion every', 'CTCAE v4.', '24-48 hours until BP is', 'controlled or at max dose', 'of Rx', 'Step 2) If BP still not', 'controlled, add another', 'anti-hypertensive Rx, a', 'LA DHP CCB, ACE1,', 'ARB, or ABB; increase', 'dose of this drug as', 'described in Step 1', 'Step 3) If BP still not', 'controlled, add 3rd drug', 'from the list of anti-', 'Protocol Version Date:16Aug2018']\n\n###\n\n", "completion": "END"}